Image: CC/L. academia
1. Treating patients with captopril after acute MI with asymptomatic LV dysfunction reduces mortality from cardiovascular causes (i.e., atherosclerotic heart disease, progressive heart failure).
2. The captopril group experienced lower rates of hospitalization due to heart failure and recurrent MI.
Study Rundown: The SAVE trial was the first to demonstrate that treating patients with acute MI and asymptomatic LV dysfunction with ACE-I reduces morbidity and mortality. These benefits are thought to result from ACE-Is slowing the remodeling process that takes place after patients suffer MIs. These findings have since been replicated in other trials (e.g., TRACE trial), systematic reviews, and meta-analyses.
In patients suffering from an acute MI and asymptomatic LV dysfunction, early initiation of and continued treatment with captopril can significantly reduce cardiovascular mortality, hospitalization due to heart failure, and recurrent MIs.
Please click to read the study in the NEJM (New England Journal of Medicine)
EvidencePulse™by 2 Minute Medicine®
How does SAVE apply to your patient?
Describe your patient and EvidencePulse weighs this trial against later evidence and current guidelines, with citations.
For a fuller review of the evidence, Deep research is a core feature of 2MM Max.
In-Depth [randomized controlled study]: The SAVE trial, first published in 1992 in NEJM, is a randomized controlled trial that sought to explore the effect of captopril on mortality in patients suffering from acute myocardial infarction (MI) and asymptomatic left ventricular (LV) dysfunction. In previous animal studies, angiotensin converting enzyme inhibitors (ACE-Is) like captopril were shown to delay ventricular remodeling, and help preserve function after MI.
The trial was conducted at 45 centres across North America. A total of 2,231 patients took part in the study and were randomized to receive either captopril or placebo. Patients were followed for a minimum of 2 years, though mean follow-up was 42 months. Treatment with captopril or placebo was initiated 3-16 days after MI (mean of 11 days). Patients randomized to receive captopril experienced significantly reduced all-cause mortality and mortality from cardiovascular causes compared to the placebo group. Specifically, captopril was associated with significant reductions in mortality from atherosclerotic heart disease and progressive heart failure. Moreover, the captopril group demonstrated significant decreases in hospitalizations because of heart failure and recurrent MIs, compared to placebo.
By Adrienne Cheung, Andrew Cheung, M.D.
Trials since this one
What later trials found on the same question.
- 1994
SHIFT In The Classics
In patients with congestive heart failure (CHF) and baseline heart rate >70 bpm, ivabradine significantly reduced the risk of heart failure hospitalization and death from heart failure compared to placebo.
- 1997
DIG In The Classics
Digoxin significantly reduced hospitalizations but had no significant effect on mortality when used to treat patients with systolic heart failure
10 more since 1992
2MM+ See every trial since SAVE
2MM+ shows the full timeline of later trials on this question, with what each one found, and lets you save trials to reading lists for rounds, journal club and boards.
Citation: Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669-77. doi: 10.1056/nejm199209033271001. PMID: 1386652.
© 2013 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: © 2 Minute Medicine
